Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Easy and effective counter-traction using a clip with a looped thread for colorectal endoscopic submucosal dissection.

Indo N, Anami T, Asaji N, Urakami S, Nishio A, Kitamura Y, Watanabe A.

Endoscopy. 2019 Aug;51(8):E233-E234. doi: 10.1055/a-0885-9550. Epub 2019 May 2. No abstract available.

PMID:
31049893
2.

[Pancreatic arteriovenous malformation perforated into the common bile and pancreatic ducts:a case report].

Urakami S, Miura S, Fujita K, Matsui S, Anami T, Watanabe A, Sugahara A, Mukai H, Yoshikawa T.

Nihon Shokakibyo Gakkai Zasshi. 2018;115(11):1011-1017. doi: 10.11405/nisshoshi.115.1011. Japanese.

PMID:
30416153
3.

Effect of tadalafil add-on therapy in patients with persistant storage symptoms refractory to α1 -adrenoceptor antagonist monotherapy for benign prostatic hyperplasia: A randomized pilot trial comparing tadalafil and solifenacin.

Urakami S, Ogawa K, Oka S, Hagiwara K, Nagamoto S, Anjiki H, Hayashida M, Yano A, Sakaguchi K, Kurosawa K, Okaneya T.

Low Urin Tract Symptoms. 2019 May;11(3):109-114. doi: 10.1111/luts.12242. Epub 2018 Sep 24.

PMID:
30251330
4.

The loss of BAP1 protein expression predicts poor prognosis in patients with nonmetastatic clear cell renal cell carcinoma with inferior vena cava tumor thrombosis.

Oka S, Inoshita N, Miura Y, Oki R, Miyama Y, Nagamoto S, Ogawa K, Sakaguchi K, Kondoh C, Kurosawa K, Urakami S, Takano T, Okaneya T.

Urol Oncol. 2018 Aug;36(8):365.e9-365.e14. doi: 10.1016/j.urolonc.2018.04.015. Epub 2018 May 28.

PMID:
29853346
5.

Recent advances in medical therapy for metastatic urothelial cancer.

Yuasa T, Urakami S, Yonese J.

Int J Clin Oncol. 2018 Aug;23(4):599-607. doi: 10.1007/s10147-018-1260-0. Epub 2018 Mar 20. Review.

6.

Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening.

Urakami S, Inoshita N, Oka S, Miyama Y, Nomura S, Arai M, Sakaguchi K, Kurosawa K, Okaneya T.

Int J Urol. 2018 Feb;25(2):151-156. doi: 10.1111/iju.13481. Epub 2017 Nov 22.

7.

Oncologic Outcome of Metastasectomy for Urothelial Carcinoma: Who Is the Best Candidate?

Nakagawa T, Taguchi S, Kanatani A, Kawai T, Ikeda M, Urakami S, Matsumoto A, Komemushi Y, Miyakawa J, Yamada D, Suzuki M, Enomoto Y, Nishimatsu H, Kondo Y, Nagase Y, Hirano Y, Okaneya T, Tanaka Y, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y.

Ann Surg Oncol. 2017 Sep;24(9):2794-2800. doi: 10.1245/s10434-017-5970-8. Epub 2017 Jul 7.

PMID:
28687875
8.

Effect of Lymphadenectomy During Radical Nephroureterectomy in Locally Advanced Upper Tract Urothelial Carcinoma.

Ikeda M, Matsumoto K, Sakaguchi K, Ishii D, Tabata KI, Kurosawa K, Urakami S, Okaneya T, Iwamura M.

Clin Genitourin Cancer. 2017 Oct;15(5):556-562. doi: 10.1016/j.clgc.2017.04.004. Epub 2017 Apr 10.

PMID:
28501481
9.

Loss of BAP1 protein expression in the first metastatic site predicts prognosis in patients with clear cell renal cell carcinoma.

Miura Y, Inoshita N, Ikeda M, Miyama Y, Oki R, Oka S, Kondoh C, Ozaki Y, Tanabe Y, Kurosawa K, Urakami S, Kohno T, Okaneya T, Takano T.

Urol Oncol. 2017 Jun;35(6):386-391. doi: 10.1016/j.urolonc.2017.02.003. Epub 2017 Mar 9.

PMID:
28284891
10.

[IMPORTANCE OF SCREENING FOR LUNG LYMPHANGIOLEIOMYOMATOSIS AMONG RENAL ANGIOMYOLIPOMA CASES].

Sakaguchi K, Oka S, Ogawa K, Nagamoto S, Kurosawa K, Urakami S, Okaneya T.

Nihon Hinyokika Gakkai Zasshi. 2017;108(4):188-193. doi: 10.5980/jpnjurol.108.188. Japanese.

11.

[Significance of Urological Surgical Treatment for Viral Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation].

Kurosawa K, Urakami S, Ishiwata K, Miyagawa J, Sakaguchi K, Fujioka M, Murata H, Inoshita N, Taniguchi S, Okaneya T.

Hinyokika Kiyo. 2016 Nov;62(11):563-567. doi: 10.14989/ActaUrolJap_62_11_563. Japanese.

12.

A PATIENT WITH RETROPERITONEAL MYXOID LIPOSARCOMA RECURRENCE WHO ACHIEVED REMARKABLE IMPROVEMENTS IN PERFORMANCE STATUS WHEN TREATED WITH COMBINATION CHEMOTHERAPY WITH GEMCITABINE AND DOCETAXEL.

Tabata M, Urakami S, Takahashi S, Sakaguchi K, Ikeda M, Kurosawa K, Okaneya T, Homma Y.

Nihon Hinyokika Gakkai Zasshi. 2016;107(4):256-260. doi: 10.5980/jpnjurol.107.256. Japanese.

13.

[Clinicopathological Study and Treatment Outcome of Retroperitoneal Soft Tissue Sarcoma].

Kurosawa K, Urakami S, Ikeda M, Tabata M, Murata H, Okaneya T.

Hinyokika Kiyo. 2015 Nov;61(11):419-26. Japanese.

14.

Editorial Comment to Effect of preoperative chemotherapy on survival of patients with upper urinary tract urothelial carcinoma clinically involving regional lymph nodes.

Urakami S, Okaneya T.

Int J Urol. 2016 Feb;23(2):158-9. doi: 10.1111/iju.13030. Epub 2015 Dec 10. No abstract available.

15.

Impact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy.

Tabata M, Ikeda M, Urakami S, Takahashi S, Sakaguchi K, Kurosawa K, Okaneya T.

Jpn J Clin Oncol. 2015 Oct;45(10):963-7. doi: 10.1093/jjco/hyv098. Epub 2015 Jun 29.

PMID:
26130451
16.

Clinical Value of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Upper Tract Urothelial Carcinoma: Impact on Detection of Metastases and Patient Management.

Tanaka H, Yoshida S, Komai Y, Sakai Y, Urakami S, Yuasa T, Yamamoto S, Masuda H, Koizumi M, Kohno A, Fukui I, Yonese J, Fujii Y, Kihara K.

Urol Int. 2016;96(1):65-72. doi: 10.1159/000381269. Epub 2015 Jun 4.

PMID:
26044598
17.

Clinical response to induction chemotherapy predicts improved survival outcome in urothelial carcinoma with clinical lymph nodal metastasis treated by consolidative surgery.

Urakami S, Yuasa T, Yamamoto S, Sakura M, Tanaka H, Hayashi T, Uehara S, Inoue Y, Fujii Y, Masuda H, Fukui I, Yonese J.

Int J Clin Oncol. 2015 Dec;20(6):1171-8. doi: 10.1007/s10147-015-0839-y. Epub 2015 May 8.

PMID:
25953680
18.

Surveillance policy for Japanese patients with stage I testicular germ cell cancer in the multi-detector computed tomography era.

Yuasa T, Inoshita N, Tanaka H, Urakami S, Yamamoto S, Fujii Y, Masuda H, Fukui I, Ishikawa Y, Yonese J.

Int J Clin Oncol. 2015 Dec;20(6):1198-202. doi: 10.1007/s10147-015-0828-1. Epub 2015 Apr 18.

PMID:
25893862
19.

Clinical outcome of patients with pancreatic metastases from renal cell cancer.

Yuasa T, Inoshita N, Saiura A, Yamamoto S, Urakami S, Masuda H, Fujii Y, Fukui I, Ishikawa Y, Yonese J.

BMC Cancer. 2015 Feb 12;15:46. doi: 10.1186/s12885-015-1050-2.

20.

Patient-perceived satisfaction after definitive treatment for men with high-risk prostate cancer: radical prostatectomy vs. intensity-modulated radiotherapy with androgen deprivation therapy.

Yamamoto S, Masuda H, Urakami S, Fujii Y, Sakamoto K, Kozuka T, Oguchi M, Fukui I, Yonese J.

Urology. 2015 Feb;85(2):407-13. doi: 10.1016/j.urology.2014.09.046. Epub 2014 Oct 30.

PMID:
25623703
21.

Laparoscopic resection of sigmoid colon cancer involving the left ureter with reconstruction by ileal interposition.

Akiyoshi T, Ueno M, Ono R, Urakami S.

Dis Colon Rectum. 2014 Oct;57(10):1241. doi: 10.1097/DCR.0000000000000202. No abstract available.

PMID:
25203382
22.

First-line combination chemotherapy with cisplatin, etoposide and ifosfamide for the treatment of disseminated germ cell cancer: re-evaluation in the granulocyte colony-stimulating factor era.

Tanaka H, Yuasa T, Fujii Y, Sakura M, Urakami S, Yamamoto S, Masuda H, Fukui I, Yonese J.

Chemotherapy. 2013;59(6):441-6. doi: 10.1159/000362498. Epub 2014 Jul 23.

PMID:
25060582
24.

Kidney cancer: decreased incidence of skeletal-related events in mRCC.

Yuasa T, Urakami S.

Nat Rev Urol. 2014 Apr;11(4):193-4. doi: 10.1038/nrurol.2014.56. Epub 2014 Mar 11. No abstract available.

PMID:
24619376
25.

Long-term oncological outcome in men with T3 prostate cancer: radical prostatectomy versus external-beam radiation therapy at a single institution.

Yamamoto S, Kawakami S, Yonese J, Fujii Y, Urakami S, Kitsukawa S, Masuda H, Ishikawa Y, Kozuka T, Oguchi M, Kohno A, Fukui I.

Int J Clin Oncol. 2014 Dec;19(6):1085-91. doi: 10.1007/s10147-013-0654-2. Epub 2013 Dec 19.

PMID:
24346487
26.

Longitudinal change in health-related quality of life after intensity-modulated radiation monotherapy for clinically localized prostate cancer.

Yamamoto S, Fujii Y, Masuda H, Urakami S, Saito K, Kozuka T, Oguchi M, Fukui I, Yonese J.

Qual Life Res. 2014 Jun;23(5):1641-50. doi: 10.1007/s11136-013-0603-6. Epub 2013 Dec 13.

27.

The processus vaginalis transection method to prevent postradical prostatectomy inguinal hernia: long-term results.

Fujii Y, Yamamoto S, Yonese J, Masuda H, Urakami S, Kitsukawa S, Sakura M, Yuasa T, Kihara K, Fukui I.

Urology. 2014 Jan;83(1):247-52. doi: 10.1016/j.urology.2013.08.037. Epub 2013 Oct 16.

PMID:
24139348
28.

Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma.

Urakami S, Fujii Y, Yamamoto S, Yuasa T, Kitsukawa S, Sakura M, Yano A, Saito K, Masuda H, Yonese J, Fukui I.

Urol Oncol. 2014 Jan;32(1):35.e1-7. doi: 10.1016/j.urolonc.2013.01.007. Epub 2013 Apr 4.

PMID:
23562233
29.

Evaluation of the RENAL nephrometry scoring system in adopting nephron-sparing surgery for cT1 renal cancer.

Yasuda Y, Yuasa T, Yamamoto S, Urakami S, Ito M, Sukegawa G, Kitsukawa S, Yonese J, Fukui I.

Urol Int. 2013;90(2):179-83. doi: 10.1159/000342971. Epub 2012 Nov 7.

PMID:
23146865
30.

Denosumab: a new option in the treatment of bone metastases from urological cancers.

Yuasa T, Yamamoto S, Urakami S, Fukui I, Yonese J.

Onco Targets Ther. 2012;5:221-9. doi: 10.2147/OTT.S30578. Epub 2012 Sep 21.

31.

Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma.

Yasuda Y, Fujii Y, Yuasa T, Kitsukawa S, Urakami S, Yamamoto S, Yonese J, Takahashi S, Fukui I.

Int J Clin Oncol. 2013 Oct;18(5):877-83. doi: 10.1007/s10147-012-0472-y. Epub 2012 Sep 11.

PMID:
22965827
32.

Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.

Yasuda Y, Saito K, Yuasa T, Kitsukawa S, Urakami S, Yamamoto S, Yonese J, Takahashi S, Fukui I.

Int J Clin Oncol. 2013 Oct;18(5):884-9. doi: 10.1007/s10147-012-0454-0. Epub 2012 Aug 11.

PMID:
22886358
33.

Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin.

Saito K, Urakami S, Komai Y, Yasuda Y, Kubo Y, Kitsukawa S, Okubo Y, Yamamoto S, Yonese J, Fukui I.

BJU Int. 2012 Nov;110(10):1478-84. doi: 10.1111/j.1464-410X.2012.11153.x. Epub 2012 Apr 23.

34.

Long-term oncological outcome and risk stratification in men with high-risk prostate cancer treated with radical prostatectomy.

Yamamoto S, Kawakami S, Yonese J, Fujii Y, Urakami S, Masuda H, Numao N, Ishikawa Y, Kohno A, Fukui I.

Jpn J Clin Oncol. 2012 Jun;42(6):541-7. doi: 10.1093/jjco/hys043. Epub 2012 Mar 28.

PMID:
22457326
35.

[Docetaxel-based combination chemotherapy for castration-resistant prostate cancer].

Urakami S, Shiina H, Igawa M.

Nihon Rinsho. 2011 Jun;69 Suppl 5:531-7. Japanese. No abstract available.

PMID:
22208039
36.

Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel.

Ito M, Saito K, Yasuda Y, Sukegawa G, Kubo Y, Numao N, Kitsukawa S, Urakami S, Yuasa T, Yamamoto S, Yonese J, Fukui I.

Urology. 2011 Nov;78(5):1131-5. doi: 10.1016/j.urology.2011.07.1416.

PMID:
22054387
37.

Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.

Yuasa T, Tsuchiya N, Urakami S, Horikawa Y, Narita S, Inoue T, Saito M, Yamamoto S, Yonese J, Fukui I, Nakano K, Takahashi S, Hatake K, Habuchi T.

BJU Int. 2012 May;109(9):1349-54. doi: 10.1111/j.1464-410X.2011.10534.x. Epub 2011 Aug 25.

38.

Outcome of antegrade radical prostatectomy with intended wide resection in prostate cancer patients with a preoperative serum PSA level >100 ng/ml.

Urakami S, Yonese J, Yamamoto S, Yuasa T, Kitsukawa S, Numao N, Kubo Y, Ito M, Sukegawa G, Yasuda Y, Ishikawa Y, Fukui I.

Urol Int. 2011;87(2):175-81. doi: 10.1159/000328048. Epub 2011 Aug 18.

PMID:
21849759
39.

Identification of lymphatic pathway involved in the spreading of prostate cancer by fluorescence navigation approach with intraoperatively injected indocyanine green.

Inoue S, Shiina H, Arichi N, Mitsui Y, Hiraoka T, Wake K, Sumura M, Honda S, Yasumoto H, Urakami S, Matsubara A, Igawa M.

Can Urol Assoc J. 2011 Aug;5(4):254-9. doi: 10.5489/cuaj.10159.

40.

Rare complication of a sigmoid colon perforation after a kidney transplant with an artificial vascular graft.

Inoue S, Shiina H, Arichi N, Mitusi Y, Hiraoka T, Wake K, Sumura M, Honda S, Urakami S, Igawa M.

Exp Clin Transplant. 2011 Jun;9(3):207-10.

41.

Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis.

Yuasa T, Urakami S, Yamamoto S, Yonese J, Saito K, Takahashi S, Hatake K, Fukui I.

Clin Exp Metastasis. 2011 Apr;28(4):405-11. doi: 10.1007/s10585-011-9379-7. Epub 2011 Mar 3.

PMID:
21365325
42.

Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer.

Yuasa T, Urakami S, Yamamoto S, Yonese J, Nakano K, Kodaira M, Takahashi S, Hatake K, Inamura K, Ishikwa Y, Fukui I.

Urology. 2011 Apr;77(4):831-5. doi: 10.1016/j.urology.2010.12.008. Epub 2011 Feb 12.

PMID:
21316083
43.

Impact of a novel, extended approach of perineal radical prostatectomy on surgical margins in localized prostate cancer.

Inoue S, Shiina H, Sumura M, Urakami S, Matsubara A, Igawa M.

BJU Int. 2010 Jul;106(1):44-8. doi: 10.1111/j.1464-410X.2009.09180.x. Epub 2010 Jan 8.

44.

Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials.

Regan MM, O'Donnell EK, Kelly WK, Halabi S, Berry W, Urakami S, Kikuno N, Oh WK.

Ann Oncol. 2010 Feb;21(2):312-8. doi: 10.1093/annonc/mdp308. Epub 2009 Jul 24.

45.

Superoxide dismutase analog (Tempol: 4-hydroxy-2, 2, 6, 6-tetramethylpiperidine 1-oxyl) treatment restores erectile function in diabetes-induced impotence.

Kawakami T, Urakami S, Hirata H, Tanaka Y, Nakajima K, Enokida H, Shiina H, Ogishima T, Tokizane T, Kawamoto K, Miura K, Ishii N, Dahiya R.

Int J Impot Res. 2009 Nov-Dec;21(6):348-55. doi: 10.1038/ijir.2009.28. Epub 2009 Jun 25.

46.

Retrospective analysis of the distance between the neurovascular bundle and prostate cancer foci in radical prostatectomy specimens: its clinical implication in nerve-sparing surgery.

Inoue S, Shiina H, Hiraoka T, Mitsui Y, Sumura M, Urakami S, Igawa M.

BJU Int. 2009 Oct;104(8):1085-90. doi: 10.1111/j.1464-410X.2009.08592.x. Epub 2009 Apr 17.

47.

Five-year longitudinal effect of radical perineal prostatectomy on health-related quality of life in Japanese men, using general and disease-specific measures.

Inoue S, Shiina H, Hiraoka T, Wake K, Sumura M, Honda S, Urakami S, Igawa M, Usui T.

BJU Int. 2009 Oct;104(8):1077-84. doi: 10.1111/j.1464-410X.2009.08491.x. Epub 2009 Mar 13.

48.

Nerve growth factor combined with vascular endothelial growth factor enhances regeneration of bladder acellular matrix graft in spinal cord injury-induced neurogenic rat bladder.

Kikuno N, Kawamoto K, Hirata H, Vejdani K, Kawakami K, Fandel T, Nunes L, Urakami S, Shiina H, Igawa M, Tanagho E, Dahiya R.

BJU Int. 2009 May;103(10):1424-8. doi: 10.1111/j.1464-410X.2008.08129.x. Epub 2008 Oct 14.

49.

Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells.

Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, Majid S, Igawa M, Dahiya R.

Int J Cancer. 2008 Aug 1;123(3):552-60. doi: 10.1002/ijc.23590. Retraction in: Int J Cancer. 2017 Oct 1;141(7):1492.

50.

Long-term control or possible cure? Treatment of stage D2 prostate cancer under chemotherapy using cisplatin and estramustine phosphate followed by maximal androgen blockade.

Urakami S, Shiina H, Sumura M, Honda S, Wake K, Hiraoka T, Inoue S, Ishikawa N, Igawa M.

Int Urol Nephrol. 2008;40(2):365-8.

PMID:
18092143

Supplemental Content

Loading ...
Support Center